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Ptenpackaged into compact structures–primordial follicles–which remain inert for
prolonged intervals until individual follicles resume growth via a process known as primordial follicle
activation. Here we show that the phosphoinositide 3-kinase (PI3K) signalling pathway controls primordial
follicle activation through the forkhead transcription factor Foxo3. Within oocytes, Foxo3 is regulated by
nucleocytoplasmic shuttling. Foxo3 is imported into the nucleus during primordial follicle assembly, and is
exported upon activation. Oocyte-speciﬁc ablation of Pten resulted in PI3K-induced Akt activation, Foxo3
hyperphosphorylation, and Foxo3 nuclear export, thereby triggering primordial follicle activation, deﬁning
the steps by which the PI3K pathway and Foxo3 control this process. Inducible ablation of Pten and Foxo3 in
adult oocytes using a new tool for genetic analysis of the germline, Vasa-CreERT2, showed that this pathway
functions throughout life. Thus, a principal physiologic role of the PI3K pathway is to control primordial
follicle activation via Foxo3.
© 2008 Elsevier Inc. All rights reserved.Introduction
Primordial follicles, each comprised of a single oocyte and a
surrounding layer of somatic granulosa cells, are formed early in life
and represent a ﬁnite resource that must be safeguarded and
efﬁciently utilized. The depletion of primordial follicles culminates
in reproductive senescence or menopause, leading to the acceleration
of many age-associated changes in women, such as reduced bone
density (Block, 1952; Lobo, 2007). Primordial follicle activation is the
irreversible, metered process by which primordial follicles are
continually recruited to initiate follicle maturation (McGee and
Hsueh, 2000). This process begins immediately after follicle assembly
within a few days of birth and is gonadotropin-independent (Mason et
al., 1986; Peters et al., 1973). Follicle growth is irreversible, and follicles
that have initiated growth either complete the process (culminating in
ovulation), or undergo atresia at some stage of their maturation. The
irreversibility of this process and the limited supply of primordial
follicles further suggest that primordial follicle activation is likely to be
tightly regulated. Yet, the molecular pathway(s) regulating primordial
follicle activation remain ill-deﬁned, limiting our ability to understand
this fundamental aspect of ovarian development and function that
inﬂuences both fertility and the menopause.
The Foxo family of forkhead transcription factors (Foxo1, Foxo3,
Foxo4, and Foxo6) participates in diverse processes including cell
proliferation, apoptosis, stress resistance, differentiation, and meta-(D.H. Castrillon).
l rights reserved.bolism (Accili and Arden, 2004). Foxo1, Foxo3, and Foxo4 are highly
expressed in most tissues, and share partially overlapping functions,
whereas Foxo6 expression appears to be restricted to the brain.
Consistent with their participation in diverse processes, the Foxos are
regulated by a variety of mechanisms including phosphorylation,
acetylation, and ubiquitination (van der Horst and Burgering, 2007).
Recently, we showed that the forkhead transcription factor Foxo3 is a
master regulator and suppressor of primordial follicle activation, the
ﬁrst such factor to be deﬁned. In Foxo3 knockout mice, primordial
follicles are assembled normally (John et al., 2007) but then
immediately undergo global activation, resulting in a distinctive
syndrome of ovarian hyperplasia, follicle depletion, premature ovarian
failure, and infertility (Castrillon et al., 2003; Hosaka et al., 2004).
However, many basic questions regarding the regulation of Foxo3 and
its role in the suppression of primordial follicle activation remain
unanswered. For example, it is not known if Foxo3 is part of a
mechanism that actively controls the decision to trigger oocyte
growth, or if Foxo3 mutation promotes follicle activation via some
other, less direct mode of action.
The phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway is
an important regulator of cell proliferation and survival, widely
studied because of its participation in cancer and other disease
processes (Cully et al., 2006). More recently, PI3K pathway compo-
nents including Pten have been implicated in stem cell maintenance
and the regulation of organ size (Groszer et al., 2001; Yilmaz et al.,
2006) suggesting that this pathway plays general, albeit incompletely
understood roles in tissuemaintenance. PI3K catalyzes the production
of the phosphoinositide PI(3,4,5)P3 (PIP3) from PI(4,5)P2 in the
198 G.B. John et al. / Developmental Biology 321 (2008) 197–204plasma membrane, resulting in membrane recruitment, phosphoryla-
tion, and activation of Akt. Pten serves as a potent PI3K antagonist by
removing the 3′ phosphate from PIP3 (Engelman et al., 2006), thereby
inhibiting Akt. Activated, phosphorylated Akt in turn phosphorylates a
wide range of direct intracellular targets containing a minimal Akt
recognition motif, including Gsk3, Bad, Tsc2, and the Foxos, among
many others; at least 20 bona ﬁde Akt substrates have been identiﬁed
(Brunet et al., 1999; Manning and Cantley, 2007). However, it has been
difﬁcult in most experimental systems to fully deﬁne the physiologi-
cally relevant substrates and their relative contributions in mediating
the biological effects of PI3K–Akt signalling.
In this paper, we show that the PI3K–Akt pathway has a key role in
the initiation of oocyte growth (and hence in the maintenance of
oocytes) and acts via Foxo3. Oocyte-speciﬁc Pten ablation resulted in
Akt hyperactivation, Foxo3 hyperphosphorylation, and Foxo3 nuclear
export, culminating in global primordial follicle activation and
premature ovarian failure. Surprisingly, oocyte-speciﬁc ablation of
Pten and Foxo3 resulted in virtually identical phenotypes of global
primordial follicle activation, arguing that Foxo3 is the primary, if not
sole effector of PI3K–Akt signalling in this physiologic context.
Pharmacologic inhibition of PI3K suppressed the Pten but not the
Foxo3 ovarian phenotype, further establishing that Foxo3 lies down-
stream of Pten. Our results demonstrate that Foxo3 is the prime
effector of the PI3K–Akt pathway in the context of primordial follicle
activation and that, surprisingly, the only essential role of Pten within
the oocyte is to regulate Foxo3.
Materials and methods
Mouse strains, breeding, and analysis
This study was approved by an Institutional Animal Care and Use
Committee. All alleles were in an FVB/n background (backcrossed at
least n=6 generations). Genotyping of the Vasa-Cre, R26R, Pten, and
Foxo3 alleles was performed on tail DNA using multiplexed PCR
protocols as described (Castrillon et al., 2003; Gallardo et al., 2007; Li
et al., 2002; Soriano, 1999); the protocol for Vasa-CreERT2was the same
as for Vasa-Cre. Vasa-Cre/+mice were bred to Foxo3L/L homozygotes to
obtain Vasa-Cre; Foxo3L/+ male progeny; males must be used for the
second generation cross because of a potent maternal effect observed
with Vasa-Cre (Gallardo et al., 2007). The Vasa-Cre transgene affects
Cre-mediated recombination in germ cells and thus, Vasa-Cre carriers
cannot transmit the L allele; e.g. Vasa-Cre; Foxo3L/+ mice can only
transmit the null (−) or wt (+) Foxo3 alleles. Vasa-Cre; Foxo3L/+ males
were crossed to Foxo3L/L females to generate experimental Vasa-Cre;
Foxo3−/L females and sibling controls. An analogous strategy was
employed to generate Vasa-Cre; Pten−/L animals and sibling controls.
Pten ﬂoxed (Li et al., 2002) and R26R mice (Soriano, 1999) were
purchased from Jackson Laboratories. Ovaries from at least n=3
experimental and n=3 control animals were evaluated for each
timepoint in all analyses.
Tissue processing, immunohistochemistry and immunoﬂuorescence
Tissue sections from experimental and control samples were placed
on the same slide to ensure identical processing; at least n=3 slides
were evaluated for each antibody. For immunohistochemistry, tissues
were ﬁxed in 10% formalin 1–12 h, then processed and embedded in
parafﬁn. 5 μm sections were deparafﬁnized in xylene, and hydrated in
anethanol series. Slideswere subjected to antigen retrieval by boiling in
10 mM NaCitrate and cooled at RT×20 min. Antibodies and titers used
were: Foxo11:100 (Santa Cruz # sc-11350), Foxo4 1:200 (Santa Cruz #
sc-5221), Pten 1:100 (Cell Signalling # 9559), p-Akt (Ser473) 1:50 (Cell
Signalling # 9271), Foxo3 1:200 (Santa Cruz # sc-11351), p-Foxo3
(Thr32) 1:200 (Upstate # 07-695), p-mTOR (Ser2448) (Cell Signalling #
2976), p-S6 Ribosomal protein (Ser235/236) (Cell Signalling # 4857)and p-4E-BP1 (Thr70) (Cell Signalling # 9455). The detection system
was Immpress (Vector, Burlingame, CA).
For immunoﬂuorescence, tissues were ﬁxed in 4% paraformalde-
hyde overnight at 4° and embedded in OCT. Frozen sections (5 μm)
were obtained and detection of PIP3 was performed as described
(Kitamura et al., 2004) with Biotin-PIP3 (1:100) (Echelon Biosciences
# Z-B345b) and streptavidin-alexa ﬂuor 488 (1:200) (Invitrogen #
S11223). Images were obtained on an Olympus BX51 microscope
equipped for epiﬂuorescence.
Wholemount X-gal staining was performed as described (Gallardo
et al., 2007).
Organ culture and histomorphometry
Ovaries were photographed after explantation and at 4 and 8 days
and the relative ovarian volume was approximated by the equation
V=(long diameter×short diameter2). Average oocyte diameter was
determined on H and E tissue sections per the long diameter of
oocytes with nuclei in the plane of section (at least nN100 such
oocytes were analyzed per ovary). Ovaries were cultured (37°, 5% CO2)
on Transwell Permeable supports (Costar, catalog # 3413) in
Waymouth's medium (Invitrogen catalog # 11220-035) supplemented
with 10% fetal bovine serum, 0.23 mM Pyruvic acid, 3 mg/ml BSA, 1×
ITS supplement (Invitrogen, catalog # 51300-044) and 1× Antibiotic–
Antimycotic (Invitrogen catalog # 15240-062). PI3K inhibition was
performed by addition of 25 μM Ly294002 (Cell Signalling Technol-
ogies, catalog # 9901) to the media.
Generation of VasaCreERT2 transgenic mice and tamoxifen administration
To generate the pVasaCre-ERT2 construct used for transgenesis,
the SV40 promoter fragment (SalI fragment) was removed from pCre-
ERT2 (Feil et al., 1997) by SalI digestion/religation. A polylinker was
then inserted by annealing oligos 5′-CTAGGTCGACGGCGCGCCG-
CGGCCGCTTAATTAA-3′ and 5′-GATCAATTAATTCGCCGGCGCCG-
CGCGGCAGCTG-3′ and cloning into the AvrII site. The Vasa promoter
fragment from pVasaCre (Gallardo et al., 2007) was released with AscI
and PacI and cloned into the AscI and PacI sites of the above polylinker.
The resulting 11,666 bp plasmid was linearized with SalI, puriﬁed on
an Elutip-D column (Schleicher and Schuell) and microinjected into
FVB/n oocytes by standard protocols (Nagy et al., 2003) at the UT
Southwestern Transgenic Core Facility. Lines with transgene integra-
tion were identiﬁed by Southern blot, and further validated by
Northern analysis. Total RNA (10 μg) was prepared from adult tissues
using Tripure reagent (Roche), electrophoresed on a 1% formaldehyde
gel, transferred to Hybond N+, probed with Cre and reprobed with
GAPDH as a loading control. One line with high expression in testis
and ovary (but not any other somatic tissues) was selected for further
analysis and validation by crossing with R26R (Soriano,1999). This line
was backcrossed to FVB/n for 6 generations.
Tamoxifen (Sigma, catalog # T5648) was resuspended at 100 mg/
ml in 100% ethanol and further diluted with corn oil (Sigma, catalog #
C8267) to a ﬁnal concentration of 20 mg/ml. Intraperitoneal
injections (2 mg tamoxifen/100 μl corn oil) were given qD for three
consecutive days. Tissues were collected 24 h following the last
injection.
To exclude the possibility that tamoxifen might affect follicle
growth, wild-type animals (n=6) were subjected to tamoxifen
treatment. There was no evidence of increased activation three
weeks after treatment: there was no alteration in follicle counts
including the ratio of primordial to growing follicles, and there was no
increase in oocyte diameter or change inpregranulosa cellmorphology
(data not shown). To exclude the possibility that the Vasa-CreERT2 allele
results in altered follicle growth dynamics, ovaries (n=6 Vasa-CreERT2
females) were similarly analyzed and found to be morphologically
unaltered (data not shown).
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Foxo3 localizes to the oocyte and undergoes nucleocytoplasmic shuttling
To begin to understand the role of Foxo3 in the suppression of
primordial follicle activation, the Foxo3 protein was localized within
mouse ovary tissue sections. Although prior mRNA in situ
hybridization studies revealed widespread Foxo3 expression
throughout the ovary (Castrillon et al., 2003; Richards et al.,
2002), the protein itself is detectable only within oogonia and
oocytes (Fig. 1A). The closely related forkhead transcription factors
Foxo1 and Foxo4 are not similarly localized to the oocyte (Fig. S1),
rationalizing the unique, nonredundant role of Foxo3 in oogenesis
(Paik et al., 2007; Tothova et al., 2007). At post-natal day (PD) 1,
Foxo3 protein was cytoplasmic within most oogonia (Fig. 1A). By
PD3, however, the protein had partially translocated to the nucleus
and was detectable in both cytoplasm and nucleus in the great
majority of follicles (Fig. 1B). By PD14, Foxo3 had completely
translocated to the nucleus (Figs. 1A, B).
Foxo3 undergoes a number of post-translational modiﬁcations that
regulate its activity, subcellular localization, and stability including
acetylation, ubiquitylation, and phosphorylation by the kinases Ikkβ,
Sgk, Cdk2, Dyrk1, Jnk, Ampk and Akt (Greer et al., 2007a; Greer et al.,
2007b; van der Horst and Burgering, 2007). We speculated that the
observed developmental translocation of Foxo3 protein was mediated
by phosphorylation. Consistent with this hypothesis, a phospho-
speciﬁc antibody that detects Foxo3 phosphorylated at its Akt
consensus phosphorylation site RPRSCT (Thr32) detected p-Foxo3
(Thr32) in oocytes at PD3 (Fig. 1C). Furthermore, p-Foxo3 (Thr32)
localized exclusively to the cytoplasm, suggesting that phosphoryla-Fig. 1. Foxo3 nucleocytoplasmic shuttling during ovarian development and early follicle grow
PD1–PD14. (B) Percent of follicles showing cytoplasmic (open circles), nuclear (black circ
Immunodetection of p-Foxo3 (Thr32) at PD3. Foxo3−/− control conﬁrms antibody speciﬁcity.
adult ovaries (6 weeks). Foxo3 localized to nucleus+cytoplasm in small primary follicles (2 le
panel). Bars in all panels are 20 μm.tion of Foxo3 by Akt regulates its subcellular localization within
oocytes (Fig. 1C).
The timing of Foxo3 cytoplasmic-to-nuclear import coincides with
the formation of individualized primordial follicles, which is
completed by PD3, implying that nuclear Foxo3 is essential for
suppression of follicle activation. Consistent with this interpretation,
and further suggesting that Foxo3 restricts primordial follicle
activation throughout life (see below), Foxo3 retains its nuclear
localization in adult primordial oocytes (Fig. 1D). In growing follicles
in wild-type adults, Foxo3 protein underwent a reverse shift from the
nucleus to the cytoplasm, and then appeared to be rapidly degraded
by the secondary follicle stage (Fig. 1D). The biological basis of this
Foxo3 protein degradation has not been explored, but may be the
result of ubiquitylation (van der Horst and Burgering, 2007). A prior
study found that enforced expression of a constitutively active form
of Foxo3 in maturing oocytes disrupts follicle maturation (Liu et al.,
2007), suggesting that Foxo3 degradation in growing follicles is
physiologically signiﬁcant.
Foxo3 functions speciﬁcally within oocytes to suppress primordial follicle
activation
These results suggested that although the gene is broadly
expressed, Foxo3 might function speciﬁcally within oocytes as a
molecular switch to regulate primordial follicle activation. To conﬁrm
this genetically, we employed a conditional (ﬂoxed) Foxo3L allele and a
Vasa-Cre (a.k.a. ddx4-Cre) deletor strain we previously generated
(Castrillon et al., 2003; Gallardo et al., 2007; Paik et al., 2007). Vasa-Cre
results in Cre-mediated recombination in N95% of oocytes in Rosa26
β-galactosidase reporter (R26R) mice (Soriano, 1999) by PD3, with noth. (A) Immunolocalization of Foxo3 in Foxo3+/+ and Foxo3−/− (negative control) ovaries,
les), or nuclear+cytoplasmic Foxo3 protein localization (gray circles) at PD1–14. (C)
(D) Nuclear to cytoplasmic translocation and degradation during early follicle growth,
ft panels), but the protein was consistently cytoplasmic in larger primary follicles (right
Fig. 2. Foxo3 functions within oocytes to suppress primordial follicle activation. (A
Ovarian hypertrophy in Vasa-Cre; Foxo3−/L female relative to sibling control. Bar=1 mm
(B) Global follicle activation in Vasa-Cre; Foxo3−/L ovary; H and E-stained tissue section
Fig. 3. Pten maintains egg supply and prevents ovarian failure. Upper panels: Vasa-Cre
E-stained sections; size bars=(left to right) 20 μm, 100 μm, and 100 μm. At 16 weeks
follicles, signifying complete ovarian failure. PD21 insets show primordial follicle inwil
normal primordial follicles in control ovary and stromal overgrowth/complete absenc
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.recombination in other ovarian cell types, andminimal recombination
in other tissues (Gallardo et al., 2007). Ovaries from 3 week-old Vasa-
Cre; Foxo3−/L females were dramatically enlarged relative to sibling
controls (Fig. 2A), and histologic analysis demonstrated that this
ovarian enlargement was due to global primordial follicle activation
(Fig. 2B). These results constitute formal genetic proof that Foxo3
functions speciﬁcally within oocytes to suppress primordial follicle
activation, at least early in life.
Essential role of Pten and PI3K–Akt signalling in primordial follicle
activation
To determine if Foxo3 in the context of primordial follicle
activation is regulated primarily by PI3K–Akt signalling, we con-
ditionally deleted the Pten gene in oocytes with Vasa-Cre and the
previously described ﬂoxed allele PtenL (Li et al., 2002). Consistent
with prior results (Reddy et al., 2008), Vasa-Cre; Pten−/L ovaries,; Pten−
, contr
d-type
e of fowhich have Pten-null oocytes, were dramatically enlarged by PD21;
histologic analysis showed that this was due to widespread
primordial follicle activation (Fig. 3). This conﬁrms that Pten serves
an essential physiologic role in the suppression of primordial follicle
activation; in addition to Foxo3, it is the only other such factor
identiﬁed (Castrillon et al., 2003). Surprisingly, in breeding tests with
wild-type males, Vasa-Cre; Pten−/L females were initially fertile,
although they exhibited a dramatic age-dependent decrease in
fertility, having no more than two litters. Thus, within oocytes, Pten
is speciﬁcally required for primordial follicle activation but not
subsequent steps of oocyte growth, ovulation, or fertilization, a
property it shares with Foxo3 (Castrillon et al., 2003; John et al.,
2007). All progeny analyzed (n=10) were heterozygous for the null
Pten allele (data not shown), showing that the observed fertility
was not due to “escaper” oocytes that failed to undergo Cre-mediated
recombination. That the Vasa-Cre Foxo3 and Pten mutant phenotypes
have similar global activation phenotypes argues that Foxo3 is the
chief physiologic target of the PI3K–Akt signalling pathway in the
context of primordial follicle activation.
Oocyte Foxo3 is regulated by PI3K–Akt signalling
To conﬁrm this hypothesis, we analyzed the status and subcellular
localization of pathway components within oocytes. In control
ovaries, Pten was readily detectable in primordial oocytes, where it
localized to both nucleus and cytoplasm, but was undetectable in
Vasa-Cre; Pten−/L oocytes, as expected (Fig. 4). Pten loss resulted in a
dramatic increase of membrane-associated PIP3 in oocytes at PD3,
promoting Aktmembrane recruitment and activation, as evidenced by
increased membrane-associated p-Akt. This increased Akt activity led
to Foxo3 hyperphosphorylation and nuclear export (Fig. 4). We
observed no evidence of mTOR pathway activation (by analyzing p-
mTOR, p-S6K, and p-4EBP) in PD3 Vasa-Cre; Pten−/L oocytes (data not/L and control ovaries at PD3, PD21, and 16 weeks; size bars=1 mm. Lower panels, H and
ols have numerous primordial follicles whereas Vasa-Cre; Pten−/L ovaries are devoid of
(arrow) and absence of primordial follicles in Vasa-Cre; Pten−/L ovary. 16 wk insets show
llicles in Vasa-Cre; Pten−/L ovary. PD21 and 16 wk insets are not at same magniﬁcation.
Fig. 4. Pten regulates primordial follicle activation via PI3K and Foxo3. Pten ablation leads to increased PIP3, Akt activation, Foxo3 hyperphosphorylation, and nuclear export. Panels
show Pten, PIP3, p-Akt (Ser473), Foxo3 and p-Foxo3 (Thr32) in PD3 ovaries counterstained with hematoxylin or DAPI (PIP3).
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activated at much later stages of follicle growth (John et al., 2007), it
does not appear to be a part of the mechanism that triggers follicle
growth, further underscoring the role of Foxo3 as the prime effector of
PI3K–Akt signalling in primordial follicle activation.
Pharmacologic inhibition studies conﬁrm pathway linearity and that
Foxo3 is downstream of Pten
To conﬁrm that primordial follicle activation is regulated via the
linear pathway (Pten–PI3K–Akt–Foxo3) suggested by these observa-
tions, ovaries were explanted at birth and cultured for 8 days in the
presence of the PI3K inhibitor Ly294002. Untreated Vasa-Cre; Pten−/L
and Vasa-Cre; Foxo3−/L ovaries grew more rapidly than controls.
Ly294002 suppressed growth of Vasa-Cre; Pten−/L but not Vasa-Cre;
Foxo3−/L ovaries, and measurements of average oocyte diameter, a
more direct indicator of primordial follicle activation (Fig. 5) also
showed that Ly294002 had a signiﬁcant effect in Vasa-Cre; Pten−/L but
not Vasa-Cre; Foxo3−/L ovaries (p=2.6x10×10−7 vs. 0.26, Student's T
Test). Although it is possible that Ly294002 may have inhibited
additional PI3K family members, these results demonstrate that the
Pten (but not Foxo3) ovarian phenotype is PI3K-dependent, consis-
tent with the above linear, ordered pathway where Pten regulates
oocyte growth via P13K, PIP3, Akt, and Foxo3. Furthermore, theseFig. 5. Pharmacologic inhibition shows that PI3K activity is required for Pten but not Foxo3 o
untreated; dashed bars, 25 μM Ly294002. Squares = wild-type, triangles = Vasa-Cre; Pten−/L;
culture period. Ut = untreated, Ly = 25 μM LY294002. Note: The small apparent difference in
values calculated by Student's T Test.ﬁndings and the equivalence of the Pten and Foxo3 ovarian
phenotypes including their initial fertility strongly argue that the
only essential physiologic role of Pten within oocytes is to forestall
primordial follicle depletion by maintaining Foxo3 within the
nucleus.
Generation and validation of VasaCreERT2, a novel tool for inducible gene
ablation within the mouse germline
The above genetic analyses utilized a Vasa-Cre transgene that is
active starting at around embryonic day 15, and results in near-total
Cre-mediated recombination by PD3 (Gallardo et al., 2007). Our
ﬁndings were thus consistent with two alternate models. In the ﬁrst
model, PI3K–Akt signalling acts during this narrow developmental
window (E15-PD3) to endow primordial follicles with some factor(s)
that suppress follicle activation later in life, or are required only prior to
PD3. Alternatively, the PI3K–Akt pathway might function continually
throughout life to balance primordial follicle activation and preserva-
tion. To formally distinguish between these two models, an inducible,
germ cell-speciﬁc CreERT2 transgenewas generated by placing a CreERT2
cDNA under the control of the murine Vasa (Ddx4) promoter (Vasa-
CreERT2). The CreERT2 fusion protein is inactive until tamoxifen is
administered (Feil et al., 1997). Tamoxifen treatment of Vasa-CreERT2;
R26R female mice at 6 weeks of age resulted in efﬁcient (90–95%)varian phenotype. Ovaries were explanted at birth and cultured for 8 days. Solid lines,
circles = Vasa-Cre; Foxo3−/L. Graph on right shows oocyte diameters at the end of 8 day
untreated Pten−/L vs. Foxo3−/L oocytes is not signiﬁcant (p=0.40). Error bars=s. e. m.; p
Fig. 6. Ablation of Pten and Foxo3 in tamoxifen-treated adult Vasa-CreERT2 female
results in global primordial follicle activation. (A) Pten (B) Foxo3. Bar=1 mm. For both
experiments, females were treated with tamoxifen and ovaries were harvested 3week
later; controls were untreated siblings of the same genotype. Ablation of Pten and
Foxo3 resulted in identical ovarian hypertrophy phenotypes; histological examination
(H and E) conﬁrmed that ovarian hypertrophy was due to global primordial follicle
activation. Size bar=50 μm. All corresponding panels in panels A and B are at the same
magniﬁcation.
Fig. 7. Model of Foxo3 regulation by PI3K–Akt signalling pathway within oocytes in
engaging receptor tyrosine kinase (RTK) complex or other cell surface receptor is asso
thus localized to the nucleus, where Foxo3 acts to suppress primordial follicle activatio
subunits), which phosphorylates the 3′OH group of PI[4,5]P2 (PIP2) to form PI[3,4,5]P
dephosphorylating PIP3. Pten inactivation results in accumulation of PIP3 at the oocyte
thereby triggering primordial follicle activation. In this model, Pten inactivation is fun
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soocyte-speciﬁc recombination; there was no evidence of recombina-
tion prior to tamoxifen treatment (Fig. S2; see also Experimental
procedures for additional details and controls). This efﬁciency was
similar to that observed in the male germline at 3–6 weeks of age (Fig.
S2, B–D). Incidentally, since production of active β-galactosidase
requires 1) tamoxifen-induced transport of Cre from the cytoplasm
to the nucleus, 2) homologous recombination of loxP sites, 3)
transcription, mRNA transport, protein translation and transport, this
experiment reveals that primordial follicles are normally engaged in a
surprisingly high degree of metabolic activity and turnover of cellular
components.the co
ciated
n. Bind
3 (PIP
memb
ctionThe Pten–PI3K–Akt–Foxo3 pathway that regulates primordial follicle
activation functions throughout life
Vasa-CreERT2; Foxo3L/L and Vasa-CreERT2; PtenL/L females were
generated by standard genetic crosses and treated at 6 weeks of age
with tamoxifen. Ovaries were harvested following a three week
interval to permit follicle growth and scoring of follicle growth
phenotypes. Ablation of both Pten and Foxo3 in adult oocytes resulted
in identical phenotypes of ovarian hypertrophy; histologic analyses
conﬁrmed global follicle activation (Fig. 6). Similar results were
obtained at 3, 9, and 12 weeks of age (not shown). Thus, this pathway
functions throughout life to regulate the utilization of the egg supply
through Foxo3.
Discussion
Primordial follicle activation appears to be a stochastic process, but
the need to ration a ﬁnite supply of primordial follicles throughout
reproductive life suggests that this process is tightly regulated. We
speculate that activation is inﬂuenced by positive and negative
feedback loops, perhaps mediated by secreted, diffusible factors.
Although such factors have not been deﬁnitively identiﬁed (Skinner,
2005), our ﬁndings substantially advance our understanding of
ovarian biology by demonstrating that such communication is
integrated by Foxo3 and the PI3K signalling pathway acting within
the oocyte itself (see Fig. 7 for model of Foxo3 function within
oocytes).
Foxo1, Foxo3, and Foxo4 function similarly, are broadly expressed,
and share partially redundant and overlapping functions, whereas
Foxo6 is regulated differently and lacks a conserved Akt motif (van der
Heide et al., 2005). In genetic analyses of Foxo1, Foxo3, and Foxo4 in
mice, a prominent tumor suppressor phenotype was not apparent in
single gene knockouts, whereas post-natal inactivation of all three loci
resulted in lymphomas and endothelial cell neoplasms (Paik et al.,
2007). Inactivation of two of three Foxo genes gave rise to
intermediate phenotypes, clearly demonstrating that the Foxos can
compensate for one another, at least in some cell types. Given this
potential for genetic redundancy, it was initially surprising that Foxo3
has a unique, nonredundant role in the suppression of primordial
follicle activation. This may now be explained by our ﬁnding that
Foxo3 appears to be the predominant Foxo protein in oocytes. It is also
notable that at the protein level, Foxo3 is readily detectable onlyntrol of primordial follicle activation. In resting state, absence of a presumptive ligand
with diminished Akt signalling in primordial oocytes. Foxo3 is unphosphorylated and
ing of presumptive ligand activates PI3K (consisting of p85 regulatory and p110 catalytic
3) at the oocyte membrane. Pten acts as a potent negative regulator of this pathway by
rane and hyperactivation of Akt, resulting in Foxo3 phosphorylation and nuclear export,
ally equivalent to the binding of presumptative ligand at a cell surface receptor.
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broadly expressed within the ovary (Castrillon et al., 2003; Richards et
al., 2002). This observation suggests that post-transcriptional
mechanisms regulating Foxo protein stability are highly signiﬁcant
in vivo. Consistent with this idea, Foxo protein stability has been found
to be regulated by ubiquitylation and proteosomal targeting in a wide
range of experimental model systems and cell types (Huang and
Tindall, 2007; Plas and Thompson, 2003; Schisler et al., 2007).
We discovered that within oocytes, Foxo3 is phosphorylated at an
Akt site and that the phosphorylation status of this site tightly
correlates with subcellular localization (cytoplasmic vs. nuclear) in
vivo, arguing that Akt is the prime regulator of Foxo3 in the context of
primordial follicle activation. Concordantly, oocyte ablation of Pten led
to Akt hyperactivation, Foxo3 hyperphosphorylation, and export of
Foxo3 from the nucleus to the cytoplasm, resulting in follicle
activation. It is also possible that additional kinases or other types of
post-translational modiﬁcation contribute to the regulation of Foxo3
within oocytes, serving as additional layers of regulation, but our
ﬁndings argue that such modiﬁcations are not the principal mechan-
ism by which Foxo3 is regulated as a switch controlling primordial
follicle activation.
The mTOR protein participates in two distinct complexes, mTORC1
and mTORC2, with different biological functions and speciﬁcities
(Guertin and Sabatini, 2007). Our ﬁnding that oocyte Akt is
phosphorylated at S473 argues that mTORC2 is active (or becomes
activated) in primordial oocytes, since mTORC2 has recently been
shown to be primary kinase regulating Akt via phosphorylation at this
site. On the other hand, we found no evidence of increased
phosphorylation of mTORC1 targets during follicle activation. Since
at least some of these targets, including p-S6K (John et al., 2007) and
p-4EBP (unpublished data) become hyperphosphorylated in more
advanced follicles, mTORC1 activationmay be important in promoting
increased protein translation during oocyte growth, but not during
activation per se.
Along these lines, it is notable that Pten and Foxo3 are genetically
equivalent with regard to primordial follicle activation. Conditional
deletion of both genes within oocytes using the Vasa-Cre transgene
led to nearly identical phenotypes of global follicle activation. An even
more striking demonstration of this genetic equivalence is that Vasa-
Cre; PtenL/L and Vasa-Cre; Foxo3L/L females (as well as Foxo3−/− females)
are initially fertile (Castrillon et al., 2003). Thus, neither Foxo3 nor
Pten are essential for subsequent steps of follicle maturation,
ovulation, fertilization, etc. These observations are further evidence
that this pathway proceeds in a linear manner with Foxo3 down-
stream of Pten and PI3K/Akt, and that Foxo3 is the principal, if not sole
output of this pathway. While the Foxos are known to be important
effectors of PI3K/Akt signalling, we ﬁnd it somewhat surprising that a
single target, Foxo3, has such an overriding role as an effector of this
pathway within oocytes, given the diversity of potential Akt
substrates. It is also rather surprising that Pten inactivation and
resultant Akt hyperactivation within oocytes does not disrupt
subsequent steps of follicle maturation, ovulation, etc. Although it is
likely that PI3K–Akt signalling participates in other aspects of
oogenesis and follicle maturation, our ﬁndings demonstrate that this
signalling pathway has evolved to serve a particularly critical role in
primordial follicle activation.
Our investigations with Vasa-CreERT2 establish the feasibility of
conditional gene targeting in primordial oocytes. This study repre-
sents the ﬁrst example of conditional genetic inactivation in
primordial oocytes in adult animals, and thus Vasa-CreERT2 should
prove useful for a broad range of studies of oocyte activation, survival,
and aging, as well as conditional genetic analysis of themale germ line
(Fig. S2). It is also remarkable that the efﬁciency of recombinationwas
so high (90–95% of primordial oocytes), at least up to 6 weeks of age.
Primordial follicles aremitotically inactive (Hirshﬁeld,1991), and prior
radiolabelling studies suggested that primordial oocytes are alsometabolically quiescent (Bakken and McClanahan, 1978; Hirshﬁeld,
1991; Moore and Lintern-Moore, 1974; Moore et al., 1974; Roversi and
Silvestrini, 1963). However, these prior studies employed methods of
limited sensitivity. Since production of active β-galactosidase requires
1) tamoxifen-induced transport of Cre from the cytoplasm to the
nucleus, 2) homologous recombination of loxP sites, and 3) ATP-
intensive processes including transcription, mRNA transport, and
protein translation, the high efﬁciency of Cre-mediated recombination
argues that primordial follicles are normally engaged in a surprisingly
high degree of metabolic activity and turnover of cellular components.
In these respects, our observations argue that primordial oocytes
resemble neurons, a ﬁnding with intriguing implications for the age-
associated oocyte loss that leads to the menopause. We speculate that
oocytes may be subject to some of the same aging mechanisms that
contribute to age-associated neurodegeneration, including oxidative
stress and the accumulation of damaged or malfolded proteins
(Mattson and Magnus, 2006).
Lastly, our ﬁndings, including the demonstration that the pathway
functions continually in adults and not just during a more limited
stage of early development, further support the idea that defects in
PI3K signalling may contribute to certain forms of female infertility
due to primordial follicle depletion, such as premature ovarian failure
and primary amenorrhea. These ﬁndings also raise the possibility that
pharmacologic agents acting upon the PI3K pathway, several of which
are in clinical trials (Granville et al., 2006), may be useful in controlling
follicle activation, treating infertility, or forestalling the menopause.
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